Phase 3 trial comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-27. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
| Property | Value | Notes |
|---|---|---|
| Primary target | Growth hormone-releasing hormone receptor | Located on anterior pituitary somatotroph cells. |
| Receptor class | G protein-coupled receptor | Activation increases intracellular cyclic AMP. |
| Main downstream hormone | Growth hormone and insulin-like growth factor 1 | Growth hormone release precedes IGF-1 elevation. |
| Primary studied effect | Reduction in visceral adipose tissue | Measured by computed tomography in clinical trials. |
| Approximate half-life | 26–38 minutes after subcutaneous administration | Values vary by assay and study population. |
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
Cricket flour (or cricket powder) is a protein-rich powder made from crickets, using various processes. Cricket flour differs from true flours made from grains by being composed mainly of protein rather than starches and dietary fiber.
=== Pitching style === Mizell stood 6 feet 3 inches (1.91 m). A hard thrower, he had a loose and easy throwing motion. His delivery made it tricky to see the ball; Ken Boyer observed, "The guy shows you his glove, his rear, and somebody tells you it’s a strike." He was known for a high leg kick during his delivery, but this trait made it easier to steal bases against him, as Willie Mays observed. Earlier in his career, his fastball was his best pitch, but it had slowed by 1960, by which point his slow curveball was his strength. The fastball moved closer to left-handed hitters, and the curveball went low and farther away on them. Mizell also threw a slider. Control problems plagued him throughout his career, though these were not as bad in 1960.
In her 2008 book The How of Happiness, Sonja Lyubomirsky similarly argued people's happiness varies around a genetic set point. Diener warns, however, that it is nonsensical to claim that "happiness is influenced 30–50% by genetics". Diener explains that the recipe for happiness for an individual always requires genetics, environment, and behaviour too, so it is nonsensical to claim that an individual's happiness is due to only one ingredient. Only differences in happiness can be attributed to differences in factors. In other words, Lyubomirsky's research does not discuss happiness in one individual; it discusses differences in happiness between two or more people. Specifically, Lyubomirsky suggests that 30–40% of the difference in happiness levels is due to genetics (i.e. heritable). In other words, still, Diener says it makes no sense to say one person's happiness is "due 50% to genetics", but it does make sense to say one person's difference in happiness is 50% due to differences in their genetics (and the rest is due to behaviour and environment). Findings from twin studies support the findings just mentioned. Twins reared apart had nearly the same levels of happiness thereby suggesting the environment is not entirely responsible for differences in people's happiness. Importantly, an individual's baseline happiness is not entirely determined by genetics, and not even by early life influences on one's genetics.
== Career == Chen began her career at the Institute of Chemistry of Academia Sinica as assistant research fellow in 1999. She was the Director of the Institute of Chemistry from 2013 to 2019, and is currently a Distinguished Research Fellow. She is also an adjunct professor at National Taiwan University, National Chiayi University, National Taiwan Ocean University, and National Chung Hsing University. She conducts research in mass spectrometry-based bioinformatics, in relation to understanding diseases such as cancer. Since 2016, Chen has participated in the US Cancer Moonshot Initiative, providing proteogenomics expertise as representative of Academia Sinica. She is the project investigator for the Taiwan Cancer Moonshot Project, which analyzes multiomic data related to gastric cancer. She participates in the Chromosome-centric Human Proteome Project, and is the group lead of chromosome 4. Chen served as president for the Human Proteome Organization (2021-2022), the Taiwan Proteomics Society, and the Taiwan Society for Mass Spectrometry (2012-2015). She has been a council member of the Asia Oceania Human Proteome Organization since 2019. She current serves as executive director of the Taiwan Proteomics Society (2021-2023), and the Taiwan Society for Mass Spectrometry. She served on editorial boards of European Journal of Mass Spectrometry, Journal of Proteome Research, and Frontiers in Analytical Chemistry, and currently serves on the Executive Advisory Board of Proteomics.
Sources: en.wikipedia.org
Pre-existing acute or chronic liver dysfunction or family history of severe liver inflammation (hepatitis), particularly medicine related. Pregnancy 11% risk of birth defects and 30-40% risk of neuro-developmental disabilities which can be permanent Known hypersensitivity to valproate or any of the ingredients used in the preparation Urea cycle disorders Hepatic porphyria Hepatotoxicity Mitochondrial disease Pancreatitis Porphyria
LiveNation (which already operates music venues at the site) will revamp the Budweiser Stage Amphitheatre into an indoor/outdoor facility with a capacity of up to 20,000 people in the summer and nearly 9,000 in winter. Austrian company Therme Group will develop the west island. A new large facility will cover most of the island. The facility will include indoor and outdoor pools, a spa, waterslides, restaurants, and a botanical garden. Outside of the facility, it will build a 12 acres (4.9 ha) public park and beach. The projected admission price for indoor activities is about $40 per person for full-day admittance. A third company proposed to build a zip-line and adventure park but pulled out of the project. The company and the government could not come to terms on the lease. Private sector investments are expected to be about $500 million. Public sector investment was not disclosed. A review process for environmental, heritage, and public consultation will likely extend into 2023. Construction is scheduled to begin in 2024, with a 2030 completion. In February 2022, Toronto city council voted to adopt a process to create an approvals process for the Province's plan for the redevelopment of Ontario Place. This process generally follows the city's traditional development approvals process, notwithstanding Ontario Place is predominately constructed on Provincially-owned land. Based on this timeline, a rezoning application is expected in late 2022 and a site plan approval process began in 2023. The Cinesphere was closed for renovations.
Animals that commonly cause injury to plants include pests such as insects, mites, and nematodes. These variously bite or abrade plant parts such as leaves, stems, and roots, or as is common among the true bugs, pierce the plant's surface and suck plant juices. The resulting injuries may admit plant pathogens such as bacteria and fungi, which may extend the injury. Caterpillar larvae of agricultural pests such as cabbage white butterflies (Pieridae) can completely defoliate Brassica crops. Molluscs such as snails graze on plants including grasses and forbs, abrading them with their rasp-like radula; they can inflict substantial damage to crops. Grazing mammals including livestock such as cattle, too, bite off or break parts of plants including grasses, forbs, and forest trees, causing injury, and again, potentially admitting pathogens.
Sources: en.wikipedia.org
== Metabolism == The bacteria rely on the enzyme glycerol-3-phosphate dehydrogenase (GPDH). GPDH is an alternative when managing electrons that are produced during metabolism. In the absence of the electron transport chain, T. pallidum uses GPDH to recycle the NAD+ by oxidizing glycerol-3-phosphate to dihydroxyacetone phosphate and make NAD+ to keep glycolysis and other redox-dependent energy reactions. By doing this, it helps balance the ATP yield without weighing down the protein's limited supply for essential tasks. T. pallidum uses an enzyme called pyrophosphate-dependent phosphofructokinase rather than ATP as a way to save energy and optimize its limited resources. T. pallidum manages without a complete tricarboxylic acid cycle and oxidative phosphorylation by using different efficient strategies including redox balancing and substrate-level to survive the nutrient-limited host environment. T. pallidum lacks enzyme orthologs for superoxide dismutase, however it does possess a superoxide reductase, maintaining the ability to reduce reactive oxygen species. In addition, T. pallidum encodes an alkyl hydroperoxide reductase C, which allows for the reduction of hydrogen peroxide to water and alcohols. This enzyme relies on TP0919, a protein present in the cytoplasm of T. pallidum. T.pallidum primarily relies on glucose as its primary carbon source through glycolysis, but one study has proposed the bacterium uses an acetogenic-energy conservation pathway as a way to catabolize D-lactate as an alternative carbon source.
where the M over the arrow denotes that to conserve energy and momentum a third body is required (the molecularity of the reaction is three). Electron capture can be used in conjunction with chemical ionization. An electron capture detector is used in some gas chromatography systems.
Isoergine, also known as isolysergic acid amide (iso-LSA or iso-LA-819), isolysergamide, or erginine, is a serotonergic psychedelic of the ergoline and lysergamide families related to ergine (lysergic acid amide; LSA) and lysergic acid diethylamide (LSD). It is the epimer of ergine inverted at the 8 position. Along with ergine and other ergolines, isoergine occurs naturally in morning glories. It is thought to be primarily responsible for the hallucinogenic effects of morning glory seeds.
== Business model == Pilot is a vertical integration telehealth company that offers specific treatments for specific ailments. Patients complete an online assessment and pay a fee to Pilot to talk to a doctor. If treatment is recommended, the patient signs up for a monthly subscription. Medication is delivered to their specified address. Pilot acts as a wholesaler of Schedule 4 medications. Medications are supplied via partner pharmacies. In most cases, they do not offer items available through Medicare or the Pharmaceutical Benefits Scheme (PBS).
Sources: en.wikipedia.org
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.
It does not act directly on adipose tissue as a primary mechanism. Instead, it increases endogenous growth hormone, which then influences lipolysis and fat distribution. The reduction in visceral fat is an indirect pharmacodynamic effect.
Tesamorelin acts upstream at the pituitary to amplify natural pulsatile growth hormone release. Growth hormone injections provide exogenous hormone and bypass pituitary regulation. The two approaches therefore differ in feedback control and hormonal dynamics.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.